Intermittent Theta Burst Stimulation on Cognitive Impairment of Cerebral Small Vessel Disease
NCT06579664, Not applicable, Recruiting, Beijing Tiantan Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Intermittent Theta Burst Stimulation on Cognitive Impairment of Cerebral Small Vessel Disease | ClinicalTrials.gov |
| NCT number | NCT06579664 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 58 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Beijing Tiantan Hospital | ClinicalTrials.gov |
| Conditions | Cerebral Small Vessel Diseases, Cognitive Impairment | ClinicalTrials.gov |
| Interventions | iTBS, sham iTBS | ClinicalTrials.gov |
| First posted | 2024-08-30 | ClinicalTrials.gov |
| Last updated | 2025-09-08 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline in Montreal Cognitive Assessment Scale | at 90±7days after iTBS therapy | Montreal Cognitive Assessment Scale (Beijing Edition) scores from 0 to 30. A higher score indicates better cognitive function. | ClinicalTrials.gov |
| Secondary | Change from baseline in Mini-mental State Examination | at 90±7days after iTBS therapy | Mini-mental State Examination (MMSE) scores from 0 to 30. A higher score indicates better cognitive function. | ClinicalTrials.gov |
| Secondary | Change from baseline in verbal fluency test | at 90±7days after iTBS therapy | Scoring of verbal fluency test (VFT) is based on the number of words produced by the participants from a category in a given time. A higher score indicates better cognitive function. | ClinicalTrials.gov |
| Secondary | Change from baseline in trail making test | at 90±7days after iTBS therapy | Scoring of color trial test (CTT) is based on time taken to complete the test and the number of wrong answers. Shorter the test time and less the mistakes, the better the outcome. | ClinicalTrials.gov |
| Secondary | Change from baseline in Stroop Test | at 90±7days after iTBS therapy | Scoring of Stroop Test is based on time taken to complete the test and the number of wrong answers. Shorter the test time and less the mistakes, the better the outcome. | ClinicalTrials.gov |
| Secondary | Change from baseline in digital span test | at 90±7days after iTBS therapy | Digital span test scores from 0 to 24. A higher score indicates better cognitive function. | ClinicalTrials.gov |
| Secondary | Change from baseline in Hamilton Anxiety Scale | at 15±7days and 90±7days after iTBS therapy | Hamilton Anxiety Scale (HAMA) scores from 0 to 56. A lower score indicates better emotional state. | ClinicalTrials.gov |
| Secondary | Change from baseline in Hamilton Depression Scale | at 15±7days and 90±7days after iTBS therapy | Hamilton Depression Scale (HAMD) scores from 0 to 68. A lower score indicates better emotional state. | ClinicalTrials.gov |
| Secondary | Change from baseline in Pittsburgh sleep quality index | at 15±7days and 90±7days after iTBS therapy | Pittsburgh sleep quality index (PSQI) scores from 0 to 21. A lower score indicates better sleep quality. | ClinicalTrials.gov |
| Secondary | Change from baseline in The Short Physical Performance Battery(SPPB) | at 15±7days and 90±7days after iTBS therapy | SPPB scores from 0 to 12. A higher score indicates better motor ability. | ClinicalTrials.gov |
| Secondary | Change from baseline in The 5-level EuroQol five Dimensions Questionnaire | at 15±7days and 90±7days after iTBS therapy | The 5-level EuroQol five Dimensions Questionnaire (EQ-5D-5L) scores from 0 to 25. A lower score indicates better life quality. | ClinicalTrials.gov |
| Secondary | Change from baseline in 6 meter walk test | at 15±7days and 90±7days after iTBS therapy | Scoring of 6 meter walk test is based on time taken to complete the test. A lower score indicates better motor ability. | ClinicalTrials.gov |
| Secondary | Change from baseline in step-by-step walk test | at 15±7days and 90±7days after iTBS therapy | Step-by-step walk test scores from 0 to 8. A lower score indicates better motor ability. | ClinicalTrials.gov |
| Secondary | Change from baseline in 3-dimensional gait analysis (3D-IGA) | at 15±7days and 90±7days after iTBS therapy | Gait features can be assessed with 3D-IGA providing rhythm, pace, phases, joint angle and other quantitative indicators. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)